GlassScriptPhysician profile
Raam Sambandam
NPI 1528226388
$80,081.53
in general payments reported to CMS, 2019-2025
77 companies · $24K in 2025
The $24K reported for 2025 was more than what 93% of Clinical Neurophysiology providers received nationally (typical 2025 total: $435).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,912 · 2020: $2,559 · 2021: $2,846 · 2022: $11K · 2023: $12K · 2024: $25K · 2025: $24K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $25K · Food and Beverage: $17K · Consulting Fee: $15K · Travel and Lodging: $3,866 · Education: $52.95.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $25,225.00 |
| Food and Beverage | $17,334.57 |
| Consulting Fee | $14,563.50 |
| Travel and Lodging | $3,866.34 |
| Education | $52.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $26,903.21 | 2019-2025 | Kisunla, Amyvid, Emgality |
| Argenx US, INC. | $16,335.04 | 2022-2025 | Vyvgart Hytrulo, Vyvgart |
| Grifols USA, LLC | $3,676.50 | 2019-2025 | Gamunex-C |
| E.R. Squibb & Sons, L.L.C. | $3,385.54 | 2022-2023 | |
| Ucb, INC. | $3,188.96 | 2019-2025 | Zilbrysq, Rystiggo, Briviact |
| Novartis Pharmaceuticals Corporation | $2,018.52 | 2019-2025 | |
| Biogen, INC. | $1,551.05 | 2019-2025 | Tysabri, Vumerity, Leqembi |
| Abbvie INC. | $1,500.03 | 2021-2025 | Qulipta, Ubrelvy |
| Celgene Corporation | $1,407.68 | 2021-2025 | Zeposia |
| Neurocrine Biosciences, INC. | $1,355.77 | 2019-2025 | Ingrezza, Ongentys |
| Pfizer INC. | $1,227.05 | 2021-2025 | |
| Mdd US Operations, LLC | $1,170.36 | 2019-2025 | Gocovri, Gocovri, Apokyn |
| Supernus Pharmaceuticals, INC. | $1,086.63 | 2019-2025 | Qelbree |
| Teva Pharmaceuticals USA, INC. | $1,061.76 | 2019-2025 | Austedo Xr, Austedo Xr, Austedo |
| Acadia Pharmaceuticals INC | $887.63 | 2019-2025 | Nuplazid |
Show all 77 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $807.43 | 2019-2022 | |
| Livanova USA, INC. | $798.21 | 2019-2024 | Vns Therapy, Vns Therapy Sentiva Model 1000 Generator |
| Eisai INC. | $689.23 | 2019-2025 | |
| Alexion Pharmaceuticals, INC. | $611.78 | 2019-2025 | Ultomiris |
| Sk Life Science, INC. | $601.14 | 2020-2025 | |
| Csl Behring | $598.29 | 2019-2025 | Hizentra |
| Emd Serono, INC. | $519.05 | 2019-2025 | Mavenclad, Mavenclad |
| Tg Therapeutics, INC. | $482.81 | 2023-2025 | |
| Lundbeck LLC | $481.38 | 2019-2025 | Rexulti, Vyepti |
| Amneal Pharmaceuticals LLC | $481.07 | 2019-2025 | Crexont, Rytary, Lyvispah |
| Genentech USA, INC. | $477.72 | 2019-2025 | Ocrevus, Ocrevus Zunovo, Enspryng |
| Takeda Pharmaceuticals U.S.A., INC. | $441.89 | 2022-2025 | Hyqvia, Gammagard |
| Allergan, INC. | $377.21 | 2019-2022 | |
| Sunovion Pharmaceuticals INC. | $376.71 | 2019-2022 | |
| Amgen INC. | $357.99 | 2019-2025 | Uplizna, Aimovig |
| Neurelis, INC. | $297.83 | 2020-2025 | Valtoco |
| Horizon Therapeutics Plc | $285.53 | 2021-2023 | Uplizna |
| Otsuka America Pharmaceutical, INC. | $270.93 | 2023-2025 | Rexulti, Nuedexta |
| Merz Pharmaceuticals, LLC | $264.45 | 2023-2025 | Xeomin, Inbrija, Ampyra |
| Mallinckrodt Hospital Products INC. | $262.41 | 2020-2025 | Acthar |
| Abbott Laboratories | $260.82 | 2020-2022 | |
| Upsher-Smith Laboratories LLC | $231.57 | 2019-2022 | |
| Avanir Pharmaceuticals, INC. | $219.08 | 2019-2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $202.84 | 2022 | |
| Catalyst Pharmaceuticals, INC. | $194.92 | 2020-2025 | Firdapse |
| Adamas Pharmaceuticals, INC. | $185.47 | 2019-2021 | |
| Janssen Biotech, INC. | $176.63 | 2025 | |
| Acorda Therapeutics, INC | $175.50 | 2019-2021 | |
| Sumitomo Pharma America, INC. | $156.54 | 2023-2024 | Aptiom |
| Impel Pharmaceuticals INC. | $154.49 | 2023 | Trudhesa |
| Boston Scientific Corporation | $154.18 | 2020-2024 | |
| Tanabe Pharma America, INC. | $153.86 | 2020-2023 | |
| Insightec,INC | $132.63 | 2022 | |
| Alnylam Pharmaceuticals INC. | $107.44 | 2022-2023 | Onpattro |
| Banner Life Sciences, LLC | $107.17 | 2022-2023 | |
| Corium, LLC | $103.49 | 2022-2023 | Adlarity |
| Janssen Pharmaceuticals, INC | $98.11 | 2020-2023 | Spravato |
| Avion Pharmaceuticals | $96.35 | 2022-2023 | Dhivy |
| Octapharma USA, INC. | $87.44 | 2022 | |
| Ge Healthcare | $78.06 | 2023-2025 | |
| Biohaven Pharmaceuticals, INC. | $76.80 | 2021 | |
| Bausch Health US, LLC | $60.02 | 2019 | |
| Zyla Life Sciences, INC. | $56.54 | 2019-2020 | |
| Impel Pharmaceuticals LLC | $52.75 | 2025 | Trudhesa |
| Jazz Pharmaceuticals INC. | $46.68 | 2022 | |
| Life Molecular Imaging LTD | $44.14 | 2019-2025 | Neuraceq |
| C2n Diagnostics, LLC | $43.36 | 2025 | Precivityad2 |
| Grt US Holding, INC. | $41.11 | 2022 | |
| Vertical Pharmaceuticals, LLC | $40.39 | 2019 | |
| Xeris Pharmaceuticals, INC. | $35.47 | 2021-2022 | |
| Axsome Therapeutics, INC. | $34.64 | 2025 | Sunosi |
| Silk Road Medical, INC. | $33.44 | 2023 | Enroute Transcarotid Stent, Enroute Transcarotid Neuroprotection System |
| Avadel Cns Pharmaceuticals, LLC | $29.92 | 2025 | Lumryz |
| Sanofi-Aventis U.S. LLC | $28.71 | 2020-2021 | |
| Akcea Therapeutics, INC. | $23.14 | 2019 | |
| Averitas Pharma INC. | $22.71 | 2025 | Qutenza |
| Harmony Biosciences LLC | $22.00 | 2025 | |
| Kyowa Kirin, INC. | $21.85 | 2021 | |
| Aucta Pharmaceuticals, INC. | $18.36 | 2025 | Motpoly Xr |
| Strongbridge US INC. | $16.20 | 2019 | |
| Arbor Pharmaceuticals, INC. | $13.66 | 2020 | |
| Avid Radiopharmaceuticals, INC. | $4.26 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Raam Sambandam listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.